Nilay Orak Akbay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nilay Orak Akbay has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ada Salaj
Department of Cardiology, Marmara University School of Medicine, Istanbul, Turkey
1 shared publication- Alessandra Vultaggio
Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy
1 shared publication - Betül Ayşe Sin
Ankara University School of Medicine
1 shared publication - Betül Özdel Öztürk
Department of Immunology and Allergic Diseases, Ankara Bilkent City Hospital, 06800 Ankara, Turkey
1 shared publication - Dilsad Mungan
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine
1 shared publication - Elif Er Gülbezer
Division of Rheumatology, Department of Internal Medicine, Koc University School of Medicine, İstanbul, Türkiye
1 shared publication
Latest Publications
- 12 July 2026
- Published by Taylor & Francis in Immunotherapy
- p. 1-10
The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study
1. Globally, respiratory allergic disorders such as asthma and rhinoconjunctivitis constitute an immense health burden. Among these, pet allergies are particularly increasing in prevalence and can ...
- 12 July 2026
- Published by Taylor & Francis in Immunotherapy
- p. 1-10
The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study
1. Globally, respiratory allergic disorders such as asthma and rhinoconjunctivitis constitute an immense health burden. Among these, pet allergies are particularly increasing in prevalence and can ...
- Open Access
- 7 April 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009121
Current approach to the diagnostic value of aspirin provocation tests in nonsteroidal anti-inflammatory drug exacerbated respiratory disease: indications, methodology, safety, and clinical applications
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a respiratory illness characterized by chronic eosinophilic airway inflammation. Although a typical clinical history of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to NSAIDs may strongly suggest the diagnosis, history alone is often unreliable due to NSAID avoidance, atypical reactions, or incomplete symptom recognition. In this context, aspirin provocation tests remain the diagnostic gold standard for confirming N-ERD. Beyond diagnostic confirmation, aspirin provocation testing provides critical insights into disease heterogeneity and phenotyping. Different challenge routes—nasal, bronchial, and oral—allow assessment of organ-specific sensitivity and inflammatory dominance. Nasal aspirin provocation primarily reflects upper airway involvement and is particularly informative in patients with severe CRSwNP, whereas inhalational lysine-aspirin challenges highlight lower-airway bronchial hyperresponsiveness. Oral aspirin provocation, through systemic exposure, captures the full spectrum of respiratory and extra-respiratory responses and therefore best reflects global disease severity. The pattern, timing, and intensity of reactions observed during provocation testing contribute to the identification of clinically relevant N-ERD subphenotypes, such as upper-airway-dominant disease, bronchial-predominant disease, or blended reactions involving both compartments. These phenotypic distinctions have direct therapeutic implications, influencing the selection of targeted treatments, including aspirin desensitization, biologic therapies, or surgical interventions. Moreover, provocation testing remains essential prior to aspirin desensitization to ensure both diagnostic accuracy and patient safety. Aspirin provocation tests are not merely confirmatory tools but represent a cornerstone of precision-based evaluation of N-ERD, enabling refined phenotyping, risk stratification, and individualized treatment planning in this complex and heterogeneous disease.
- 7 April 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009121
Open AccessCurrent approach to the diagnostic value of aspirin provocation tests in nonsteroidal anti-inflammatory drug exacerbated respiratory disease: indications, methodology, safety, and clinical applications
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a respiratory illness characterized by chronic eosinophilic airway inflammation. Although a typical clinical history of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to NSAIDs may strongly suggest the diagnosis, history alone is often unreliable due to NSAID avoidance, atypical reactions, or incomplete symptom recognition. In this context, aspirin provocation tests remain the diagnostic gold standard for confirming N-ERD. Beyond diagnostic confirmation, aspirin provocation testing provides critical insights into disease heterogeneity and phenotyping. Different challenge routes—nasal, bronchial, and oral—allow assessment of organ-specific sensitivity and inflammatory dominance. Nasal aspirin provocation primarily reflects upper airway involvement and is particularly informative in patients with severe CRSwNP, whereas inhalational lysine-aspirin challenges highlight lower-airway bronchial hyperresponsiveness. Oral aspirin provocation, through systemic exposure, captures the full spectrum of respiratory and extra-respiratory responses and therefore best reflects global disease severity. The pattern, timing, and intensity of reactions observed during provocation testing contribute to the identification of clinically relevant N-ERD subphenotypes, such as upper-airway-dominant disease, bronchial-predominant disease, or blended reactions involving both compartments. These phenotypic distinctions have direct therapeutic implications, influencing the selection of targeted treatments, including aspirin desensitization, biologic therapies, or surgical interventions. Moreover, provocation testing remains essential prior to aspirin desensitization to ensure both diagnostic accuracy and patient safety. Aspirin provocation tests are not merely confirmatory tools but represent a cornerstone of precision-based evaluation of N-ERD, enabling refined phenotyping, risk stratification, and individualized treatment planning in this complex and heterogeneous disease.
- 1 September 2009
- Published by Elsevier in Metabolism
- Vol. 58 (9) , 1256-1262
Sex hormones and metabolic syndrome in children and adolescents
- 1 September 2009
- Published by Elsevier in Metabolism
- Vol. 58 (9) , 1256-1262
Sex hormones and metabolic syndrome in children and adolescents